No abstract

In Japan, cancer has been the leading cause of death since the 1980s. 70-80％ of cancer patients need cancer pain treatment. Currently oxycodone has a central role in cancer pain treatment, and its consumption is increasing every year. However, nausea and vomiting are produced at the start of oxycodone dosing that often leads to discontinuation of treatment. In this study, we retrospectively investigated the medical records of 112 patients who had cancer in order to examine risk factors related to nausea and vomiting at the start of oral oxycodone dosing. As a result, the incidence of nausea and vomiting was 25％ at the start of oral oxycodone dosing. Multiple logistic regression analysis showed that there were significant differences for young people under the age of 50 (odds ratio = 5.32, 95％ CI = 1.54-18.4, P = 0.008), nonsmokers (odds ratio = 8.39, 95％ CI = 1.47-48.0, P = 0.017) and gastrointestinal primary cancer (odds ratio = 4.14, 95％ CI = 1.32-13.0, P = 0.015). We revealed risk factors at the start of oral oxycodone dosing. This result provides useful knowledge on maintaining the continuity of cancer pain treatment and QOL of patients.